Inovio Pharma Releases Favorable Data From Booster DNA Vaccine Candidate For Ebola

Inovio Pharmaceuticals Inc INO announced results from a Phase 1b trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.
Ervebo is an FDA-approved vaccine to prevent ebola in individuals 18 years and older.
In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants.
Dr. Laurent Humeau, PhD, INOVIO's Chief Scientific Officer, said, "We are very encouraged by today's data, which demonstrates the versatility of our platform and reinforces our belief in DNA medicines' ability to elicit immune responses across multiple indications, from HPV-associated tumors to infectious diseases."
Related: INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates.
Dr. Angela Huttner, MD, Infectious Disease Consultant, Geneva University Hospitals, and the lead investigator of the study, said, "INO-4201 was well-tolerated and all treated participants responded to the booster vaccine. These are encouraging results since our participants were initially vaccinated with Ervebo three to seven years ago."
Price Action: INO shares are up 9.58% at $1.83 on the last check Thursday.